Loading...
•
Jun 30, 2022
AbCellera Q2 2022 Earnings Report
Announced financial results for the second quarter of 2022.
Key Takeaways
AbCellera reported total revenue of $46 million, driven by royalties associated with bebtelovimab and research fees from the partnership business. The company incurred a net loss of $7 million, or ($0.02) per share. They strengthened their balance sheet and continue to invest in technology development.
Earned $46 million in total revenue.
Incurred net loss of $7 million.
Added six programs under contract with two new partners, resulting in a cumulative total of 164 programs under contract with 38 different partners.
Started discovery on four programs, bringing the cumulative number of program starts to 88.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management.
Revenue & Expenses
Visualization of income flow from segment revenue to net income